0001438133-22-000087.txt : 20220519 0001438133-22-000087.hdr.sgml : 20220519 20220519191419 ACCESSION NUMBER: 0001438133-22-000087 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20220517 FILED AS OF DATE: 20220519 DATE AS OF CHANGE: 20220519 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BLICKENSTAFF KIM D CENTRAL INDEX KEY: 0001238913 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36189 FILM NUMBER: 22944844 MAIL ADDRESS: STREET 1: C/O MEDIVATION, INC. STREET 2: 201 SPEAR STREET, 3RD FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94105 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TANDEM DIABETES CARE INC CENTRAL INDEX KEY: 0001438133 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 204327508 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11075 ROSELLE STREET CITY: San Diego STATE: CA ZIP: 92121 BUSINESS PHONE: 858-366-6900 MAIL ADDRESS: STREET 1: 11075 ROSELLE STREET CITY: San Diego STATE: CA ZIP: 92121 4 1 wf-form4_165300203905899.xml FORM 4 X0306 4 2022-05-17 0 0001438133 TANDEM DIABETES CARE INC TNDM 0001238913 BLICKENSTAFF KIM D C/O TANDEM DIABETES CARE, INC. 11075 ROSELLE STREET SAN DIEGO CA 92121 1 0 0 0 Common Stock 2022-05-17 4 M 0 6560 9 A 8452 D Common Stock 2022-05-18 4 M 0 2205 0 A 10657 D Common Stock 2022-05-17 4 M 0 13562 73.726 A 215952 I See Footnote Common Stock 2022-05-17 4 S 0 10762 92.91 D 205190 I See Footnote Stock Option 9.0 2022-05-17 4 M 0 6560 9 A Common Stock 6560.0 0 D Warrant 73.726 2022-05-17 4 M 0 13562 73.726 A 2022-05-17 Common Stock 13562.0 0 I See Footnote Restricted Stock Unit 2022-05-18 4 M 0 2205 0 A Common Stock 2205.0 0 D Represents shares of common stock received upon exercise of a stock option award. The transaction reflects the cashless exercise of warrants to purchase common stock, at an exercise price of $73.726. Pursuant to the terms of the warrant, the shares of common stock were sold at a price equal to the average of the closing prices of the shares over the 30-day period ending three days prior to the date on which the notice of exercise was received by the Issuer. The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010. The options vested as to twenty-five percent (25%) of the underlying shares on 5/17/2018, and the remaining shares vested in thirty-six (36) equal monthly installments thereafter, subject to the terms of Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan (the 2013 Plan). The expiration date for these options is 10 years from the date of grant. The expiration dates for these warrants are May 25, 2022 (2,712 shares), and July 3, 2022 (10,850 shares). Awarded on May 18, 2021 pursuant to the 2013 Plan, as amended, and the agreements related thereto. Each restricted stock (RSU) unit represents a contingent right to receive one share of common stock of the Company. Shares will vest on the one year anniversary of the grant date, subject to the terms of the 2013 Plan. s/ Rachel Malina, Attorney-in-Fact for Kim D. Blickenstaff 2022-05-19 EX-24 2 ex-24.htm POA FOR KIM BLICKENSTAFF

POWER OF ATTORNEY

 The undersigned hereby constitutes and appoints Shannon M. Hansen, Leigh A. Vosseller, Christina X. Sun, and Rachel Malina, or any of them signing individually, the undersigned's true and lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer of Tandem Diabetes Care, Inc. (the "Company"), Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules and regulations thereunder;

(2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Forms 3, 4s and 5s and timely file such form with the SEC and any stock exchange or similar authority; and

(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

 The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform each and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and revocation, hereby ratifying and confirming all that each such attorney-in-fact, or each such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted.  The undersigned acknowledges that each of the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

 The undersigned agrees that each such attorney-in-fact may rely entirely on information furnished orally or in writing by the undersigned to each such attorney-in-fact.  The undersigned also agrees to indemnify and hold harmless the Company and each such attorney-in-fact against any losses, claims, damages or liabilities (or actions in these respects) that arise out of or are based on any untrue statement or omission of necessary facts in the information provided by the undersigned to such attorney-in-fact for purposes of executing, acknowledging, delivering and filing Forms 3, 4s or 5s (including amendments thereto) and agrees to reimburse the Company and each such attorney-in-fact for any legal or other expenses reasonably incurred in connection with investigating or defending against any such loss, claim, damage, liability or action.




 This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4s and 5s with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

 IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 21st day of April, 2022.


     By:/s/ Kim D. Blickenstaff

     Name:  Kim D. Blickenstaff
DocuSign